Physician profile
Ahmad Hamad
NPI 1235414681
$9,275.30
in general payments reported to CMS, 2019-2025
31 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $217 · 2021: $1,413 · 2022: $2,023 · 2023: $1,454 · 2024: $1,479 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,029.33 |
| Education | $165.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,811.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,451.60 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,016.02 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $924.86 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $447.42 | 2019-2025 | |
| Amgen INC. | $384.80 | 2021-2025 | Tezspire |
| Optinose US, INC. | $272.02 | 2021-2024 | |
| Abbvie INC. | $270.12 | 2022-2025 | |
| Genentech USA, INC. | $244.97 | 2020-2025 | Xolair |
| Incyte Corporation | $241.84 | 2021-2025 | Opzelura, Jakafi |
| Novartis Pharmaceuticals Corporation | $225.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.19 | 2022-2025 | Cuvitru, Takhzyro |
| Aimmune Therapeutics, INC. | $210.34 | 2022 | |
| Kaleo, INC. | $190.01 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $188.66 | 2021-2023 | Xembify, Prolastin-C Liquid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $174.65 | 2025 | Neffy |
| Csl Behring | $139.21 | 2022-2025 | Hizentra, Andembry |
| Blueprint Medicines Corporation | $132.42 | 2023-2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $106.59 | 2021-2023 | Orladeyo |
| Greer Laboratories, INC. | $105.30 | 2023-2025 | Oralair, Palforzia |
| Lilly USA, LLC | $100.24 | 2024-2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $56.04 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $54.41 | 2023-2025 | Ryaltris |
| Galderma Laboratories, L.P. | $49.60 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $47.95 | 2024-2025 | Ruconest |
| Phadia US INC. | $47.20 | 2022-2023 | Immunocap |
| Circassia INC. | $34.82 | 2019 | |
| Alk-Abello, INC | $21.00 | 2019 | |
| Merck Sharp & Dohme LLC | $18.24 | 2022 | |
| Leo Pharma INC. | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.